FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2052753013> ?p ?o ?g. }

• W2052753013 endingPage "S24" @default.
• W2052753013 startingPage "S18" @default.
• W2052753013 abstract "Large adjuvant trials, over many years, have randomised thousands of women with early breast cancer to different regimens. They have been instrumental in defining our current approach in the adjuvant setting. However in clinical practice with each patient, we still have the difficulty of targeting their specific therapy, as results relating to the average trial population are often not transferable to the individual. This review of adjuvant chemotherapy trials focuses on the heterogeneity of disease, treatment, mechanisms of chemotherapy action and risk. These issues are of key importance in our interpretation and application of results from adjuvant trials. A critical issue in adjuvant chemotherapy is identification of patients at high risk of recurrence who have chemosensitive tumours. Risk of relapse does not always correlate with chemosensitivity, and cytotoxic therapy in patients with chemorefractory disease may be ineffective and associated only with toxicity. Rather than general sensitivity to cytotoxics, we need predictive biomarkers to guide which specific therapy will be effective in a particular patient. Assessment of specific biomarkers as predictive tools may individualise care and see chemotherapy implementation as targeted agents, with tumour heterogeneity reflected in heterogeneity of intervention. Already with trastuzumab, we have a subgroup predicted by Her-2 gene amplification. Anthracyclines and taxanes, whilst widely used, do not yet have prospectively proven biomarkers to predict response. Potential biomarkers for anthracyclines include topoisomerase II alpha and markers of DNA repair dysfunction, whilst for taxanes, microtubule-associated proteins may play a role. The basal phenotype may be predictive of benefit from DNA damaging agents." @default.
• W2052753013 created "2016-06-24" @default.
• W2052753013 creator A5001784452 @default.
• W2052753013 creator A5012183444 @default.
• W2052753013 creator A5012187098 @default.
• W2052753013 creator A5024950175 @default.
• W2052753013 creator A5050421775 @default.
• W2052753013 creator A5062461129 @default.
• W2052753013 creator A5076132601 @default.
• W2052753013 date "2009-10-01" @default.
• W2052753013 modified "2023-09-26" @default.
• W2052753013 title "Adjuvant chemotherapy – the dark side of clinical trials Have we learnt more?" @default.
• W2052753013 cites W1976052438 @default.
• W2052753013 cites W1978331365 @default.
• W2052753013 cites W1980168308 @default.
• W2052753013 cites W2030796899 @default.
• W2052753013 cites W2037834300 @default.
• W2052753013 cites W2060966049 @default.
• W2052753013 cites W2073760655 @default.
• W2052753013 cites W2078647713 @default.
• W2052753013 cites W2096471659 @default.
• W2052753013 cites W2097255042 @default.
• W2052753013 cites W2105882193 @default.
• W2052753013 cites W2110426068 @default.
• W2052753013 cites W2114800396 @default.
• W2052753013 cites W2115228053 @default.
• W2052753013 cites W2116692581 @default.
• W2052753013 cites W2120512382 @default.
• W2052753013 cites W2125835228 @default.
• W2052753013 cites W2125955497 @default.
• W2052753013 cites W2125979795 @default.
• W2052753013 cites W2128936801 @default.
• W2052753013 cites W2136902656 @default.
• W2052753013 cites W2136983579 @default.
• W2052753013 cites W2138523273 @default.
• W2052753013 cites W2138929540 @default.
• W2052753013 cites W2154824518 @default.
• W2052753013 cites W2157285286 @default.
• W2052753013 cites W2164653269 @default.
• W2052753013 cites W2164789874 @default.
• W2052753013 cites W2165558968 @default.
• W2052753013 cites W2166825080 @default.
• W2052753013 cites W2169965478 @default.
• W2052753013 doi "https://doi.org/10.1016/s0960-9776(09)70267-x" @default.
• W2052753013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19914536" @default.
• W2052753013 hasPublicationYear "2009" @default.
• W2052753013 type Work @default.
• W2052753013 sameAs 2052753013 @default.
• W2052753013 citedByCount "6" @default.
• W2052753013 countsByYear W20527530132012 @default.
• W2052753013 countsByYear W20527530132015 @default.
• W2052753013 countsByYear W20527530132016 @default.
• W2052753013 countsByYear W20527530132022 @default.
• W2052753013 crossrefType "journal-article" @default.
• W2052753013 hasAuthorship W2052753013A5001784452 @default.
• W2052753013 hasAuthorship W2052753013A5012183444 @default.
• W2052753013 hasAuthorship W2052753013A5012187098 @default.
• W2052753013 hasAuthorship W2052753013A5024950175 @default.
• W2052753013 hasAuthorship W2052753013A5050421775 @default.
• W2052753013 hasAuthorship W2052753013A5062461129 @default.
• W2052753013 hasAuthorship W2052753013A5076132601 @default.
• W2052753013 hasBestOaLocation W20527530131 @default.
• W2052753013 hasConcept C121608353 @default.
• W2052753013 hasConcept C126322002 @default.
• W2052753013 hasConcept C143998085 @default.
• W2052753013 hasConcept C168563851 @default.
• W2052753013 hasConcept C185592680 @default.
• W2052753013 hasConcept C2776694085 @default.
• W2052753013 hasConcept C2777863537 @default.
• W2052753013 hasConcept C2777982462 @default.
• W2052753013 hasConcept C2779134260 @default.
• W2052753013 hasConcept C2779786085 @default.
• W2052753013 hasConcept C2781197716 @default.
• W2052753013 hasConcept C2908647359 @default.
• W2052753013 hasConcept C530470458 @default.
• W2052753013 hasConcept C535046627 @default.
• W2052753013 hasConcept C55493867 @default.
• W2052753013 hasConcept C71924100 @default.
• W2052753013 hasConcept C99454951 @default.
• W2052753013 hasConceptScore W2052753013C121608353 @default.
• W2052753013 hasConceptScore W2052753013C126322002 @default.
• W2052753013 hasConceptScore W2052753013C143998085 @default.
• W2052753013 hasConceptScore W2052753013C168563851 @default.
• W2052753013 hasConceptScore W2052753013C185592680 @default.
• W2052753013 hasConceptScore W2052753013C2776694085 @default.
• W2052753013 hasConceptScore W2052753013C2777863537 @default.
• W2052753013 hasConceptScore W2052753013C2777982462 @default.
• W2052753013 hasConceptScore W2052753013C2779134260 @default.
• W2052753013 hasConceptScore W2052753013C2779786085 @default.
• W2052753013 hasConceptScore W2052753013C2781197716 @default.
• W2052753013 hasConceptScore W2052753013C2908647359 @default.
• W2052753013 hasConceptScore W2052753013C530470458 @default.
• W2052753013 hasConceptScore W2052753013C535046627 @default.
• W2052753013 hasConceptScore W2052753013C55493867 @default.
• W2052753013 hasConceptScore W2052753013C71924100 @default.
• W2052753013 hasConceptScore W2052753013C99454951 @default.
• W2052753013 hasLocation W20527530131 @default.
• W2052753013 hasLocation W20527530132 @default.

• next